In the U.S., the Office of Combination Products assigns primary jurisdiction for in vitro diagnostics (CDER, CBER, or CDRH). This article shares regulatory and commercial considerations.
A major change introduced by the EU MDR is the inclusion of products without an intended medical purpose but with similar risk profiles to medical devices, such as dermal fillers.
